EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Pharmacokinetics of Approved RNA Therapeutics

Seong Jun Jo, Soon Uk Chae, Chae Bin Lee, Soo Kyung Bae iD

International Journal of Molecular Sciences · 01.01.2023 · 24 (1) · 746

DOI: 10.3390/ijms24010746 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.01.2023. Verfasst von Seong Jun Jo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Republic of Korea. Hauptthemen laut MEDLINE: Pharmacokinetics. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), Basic Science Research Program through the National Research Foundation of Korea, Research Fund of The Catholic University of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA-mediated drugs are a rapidly growing class of therapeutics. Over the last five years, the list of FDA-approved RNA therapeutics has expanded owing to their unique targets and prolonged pharmacological effects. Their absorption, distribution, metabolism, and excretion (ADME) have important clinical im-plications, but their pharmacokinetic properties have not been fully understood. Most RNA therapeutics have structural modifications to prevent rapid elimination from the plasma and are administered intravenously or subcutaneously, with some exceptions, for effective distribution to target organs. Distribution of drugs into tissues depends on the addition of a moiety that can be transported to the target and RNA therapeutics show a low volume of distribution because of their molecular size and negatively-charged backbone. Nucleases metabolize RNA therapeutics to a shortened chain, but their metabolic ratio is relatively low. Therefore, most RNA therapeutics are excreted in their intact form. This review covers not only ADME features but also clinical pharmacology data of the RNA therapeutics such as drug–drug interaction or population pharmacokinetic analyses. As the market of RNA therapeutics is expected to rapidly expand, comprehensive knowledge will contribute to interpreting and evaluating the pharmacological properties.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacokineticsDrug InteractionsChemical PhenomenaBiological Transport

Stichwörter der Autor:innen

FDA-approved RNA therapeuticsabsorptiondistributionexcretionmetabolism

Autor:innen und Institutionen

  • Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon 14662, Republic of Korea.

ORCID-Profile: Soo Kyung Bae

Förderung

  • Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI)
  • Basic Science Research Program through the National Research Foundation of Korea
  • Research Fund of The Catholic University of Korea
  • National Research Foundation of Korea
  • Ministry of Health & Welfare

Zitieren

APA

Jo, S. J., Chae, S. U., Lee, C. B., & Bae, S. K. (2023). Clinical Pharmacokinetics of Approved RNA Therapeutics. International Journal of Molecular Sciences, 24(1), 746. https://doi.org/10.3390/ijms24010746

Vancouver

Jo SJ, Chae SU, Lee CB, Bae SK. Clinical Pharmacokinetics of Approved RNA Therapeutics. International Journal of Molecular Sciences. 2023;24(1):746. doi:10.3390/ijms24010746

BibTeX
@article{Jo2023,
  author = {Jo, Seong Jun and Chae, Soon Uk and Lee, Chae Bin and Bae, Soo Kyung},
  title = {Clinical Pharmacokinetics of Approved RNA Therapeutics},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {1},
  pages = {746},
  doi = {10.3390/ijms24010746}
}
Kostenlos starten →